Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Key Points: CML LSC demonstrate increased IL-1 receptor expression and enhanced signaling response. Inhibition of IL-1 signaling using the antagonist IL-1RA enhances targeting of CML LSC in combination with TKI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317 · cited 1×
“IL-1 stimulation induces miR-146a expression, which acts as a negative feedback regulator of IL-1 signaling by inhibiting the IRAK1 and TRAF6 genes.(28,29) Our recent studies show that miR-146a is downregulated in CML CD34(1) cells, potentially contributing to increased IL-1 signaling.”
BackgroundWeber, A., Wasiliew, P., & Kracht, M. (2010) · Science Signaling · doi:10.1126/scisignal.3105cm1 · Cited by 962 · cited 10×
“Indeed, IL-1 inhibition diminishes expression of several other cytokines in CML LSC. IL-1 signaling is regulated at the level of synthesis and release, membrane receptors, and intracellular signal transduction.”
BackgroundResultInfluentialPietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689 · cited 1×
“However, chronic IL-1 exposure can drive myeloid differentiation, and chronic exposure leads to reduced HSC self-renewal.(22) Consistent with previous reports, we observed that CML LTHSC demonstrated upregulated IL-1RAP expression.”
ResultHorai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611 · cited 1×
“IL1R-deleted adult mice do not show defects in steady-state hematopoiesis.(20) The studies of Ågerstam et al(21) confirm that IL-1RAP is dispensable for normal HSC function, even under conditions of hematopoietic stress.”
BackgroundRousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5797 · Cited by 416 · cited 1×
“Currently, only a small fraction of TKI-treated CML patients can maintain TFR after discontinuing treatment.(31) Our studies support further exploration of the use of IL-1 blockade as a potential strategy to enhance LSC targeting in patients receiving TKI treatment to increase the likelihood of achieving TFR.”
ResultNF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies
Zhao, J. L., Rao, D. S., Boldin, M. P., Taganov, K. D., O'Connell, R. M., & Baltimore, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105398108 · Cited by 386
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-12-327437 · Cited by 245 · cited 1×
“However, TKI treatment fails to eliminate CML leukemia stem cells (LSC), even in patients achieving deep molecular responses.(3) Although a subset of CML CP patients are able to maintain remission after stopping TKIs, most patients require continued treatment to prevent relapse.”
BackgroundSelf-citationBarreyro, L., Will, B., Bartholdy, B., Zhou, L., Todorova, T. I., Stanley, R. F., Ben-Neriah, S., Montagna, C., Parekh, S., Pellagatti, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404699 · Cited by 201
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
Cited by
Inflammation: a key regulator of hematopoietic stem cell fate in health and disease
Pietras, E. M. (2017) · Blood · doi:10.1182/blood-2017-06-780882 · Cited by 417
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Self-citationCarey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript progenitors in CML and targeting IL-1 signaling eliminates these early progenitors(Agerstam et al., 2016; Zhang et al., 2016).”
BackgroundNeural regulation of bone and bone marrow
Maryanovich, M., Takeishi, S., & Frenette, P. S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031344 · Cited by 114
“Indeed, it was recently reported that a combination of IL-1 receptor antagonist with another BCR-ABL inhibitor nilotinib ameliorated the survival of CML mice compared with nilotinib treatment alone (Zhang et al. 2016).”
BackgroundÅgerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Metadata
- Authors
- Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., & Bhatia, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-12-08
- Volume
- 128
- Issue
- 23
- Pages
- 2671-2682
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2519666751
- Cited by
- 108
- References
- 10
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells. https://app.cochat.ai/papers/10.1182/blood-2015-11-679928
- The paper
- Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., & Bhatia, R. (2016). Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells. Blood. https://doi.org/10.1182/blood-2015-11-679928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.